

# Alexandre de Mendonça

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2628119/publications.pdf>

Version: 2024-02-01

182  
papers

11,156  
citations

31976

53  
h-index

36028

97  
g-index

184  
all docs

184  
docs citations

184  
times ranked

12661  
citing authors

#	ARTICLE	IF	CITATIONS
1	Network structure and transcriptomic vulnerability shape atrophy in frontotemporal dementia. <i>Brain</i> , 2023, 146, 321-336.	7.6	30
2	A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. <i>Applied Neuropsychology Adult</i> , 2022, 29, 112-119.	1.2	18
3	Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 158-168.	1.9	7
4	Practice effects in genetic frontotemporal dementia and at-risk individuals: a GENFI study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 336-339.	1.9	1
5	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. <i>Brain</i> , 2022, 145, 1805-1817.	7.6	27
6	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum <i>NfL</i> and <i>pNfH</i> : A Longitudinal Multicentre Study. <i>Annals of Neurology</i> , 2022, 91, 33-47.	5.3	21
7	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 10.	6.2	4
8	The Outcome of Patients with Amyloid-Negative Amnesic Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 629-640.	2.6	2
9	An Automated Toolbox to Predict Single Subject Atrophy in Presymptomatic Granulin Mutation Carriers. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-14.	2.6	3
10	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	9.0	97
11	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. <i>Cortex</i> , 2022, 150, 12-28.	2.4	2
12	Data-driven staging of genetic frontotemporal dementia using multi-modal <i>MRI</i> . <i>Human Brain Mapping</i> , 2022, 43, 1821-1835.	3.6	7
13	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. <i>Neurobiology of Aging</i> , 2022, , .	3.1	1
14	Time perspective and amnesic mild cognitive impairment. <i>Journal of Neuropsychology</i> , 2022, 16, 463-480.	1.4	1
15	Anomia is present pre-symptomatically in frontotemporal dementia due to MAPT mutations. <i>Journal of Neurology</i> , 2022, 269, 4322-4332.	3.6	1
16	The <i>CBI</i> detects early behavioural impairment in genetic frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 644-658.	3.7	1
17	Different MMSE domains are associated to cognitive decline and education. <i>Applied Neuropsychology Adult</i> , 2022, , 1-7.	1.2	3
18	Development of a sensitive trial-ready poly(GP) CSF biomarker assay for <i>C9orf72</i> -associated frontotemporal dementia and amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 761-771.	1.9	12

#	ARTICLE	IF	CITATIONS
19	New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.	21.4	700
20	Longitudinal Cognitive Changes in Genetic Frontotemporal Dementia Within the GENFI Cohort. <i>Neurology</i> , 2022, 99, .	1.1	5
21	Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 652.	9.0	31
22	Neuropsychological profile of amyloid-positive versus amyloid-negative amnesic Mild Cognitive Impairment. <i>Journal of Neuropsychology</i> , 2021, 15, 41-52.	1.4	11
23	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, 500-514.	0.8	36
24	White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 163-175.	2.6	5
25	Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. <i>Alzheimer's and Dementia</i> , 2021, 17, 969-983.	0.8	31
26	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. <i>JAMA Network Open</i> , 2021, 4, e2030194.	5.9	42
27	MRI data-driven algorithm for the diagnosis of behavioural variant frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 608-616.	1.9	10
28	Memory awareness in patients with Major Depressive Disorder. <i>Journal of Psychiatric Research</i> , 2021, 137, 411-418.	3.1	2
29	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.	12.8	140
30	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 127.	6.2	12
31	Shift of musical hallucinations to visual hallucinations after correction of the hearing deficit in a patient with Lewy body dementia: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 449.	0.8	2
32	Dissemination in time and space in presymptomatic granulin mutation carriers: a GENFI spatial chronnectome study. <i>Neurobiology of Aging</i> , 2021, 108, 155-167.	3.1	3
33	Differential early subcortical involvement in genetic FTD within the GENFI cohort. <i>NeuroImage: Clinical</i> , 2021, 30, 102646.	2.7	28
34	Disease-related cortical thinning in presymptomatic granulin mutation carriers. <i>NeuroImage: Clinical</i> , 2021, 29, 102540.	2.7	8
35	SLITRK2, an X-linked modifier of the age at onset in C9orf72 frontotemporal lobar degeneration. <i>Brain</i> , 2021, 144, 2798-2811.	7.6	7
36	Pattern of progression in MAPT-related frontotemporal dementia: Results from the GENFI study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0

#	ARTICLE	IF	CITATIONS
37	Differential synaptic marker involvement in the different genetic forms of frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
38	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 145-156.	10.2	175
39	Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 975-984.	1.9	25
40	Abnormal pain perception is associated with thalamo-cortico-striatal atrophy in <i>C9orf72</i> expansion carriers in the GENFI cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1325-1328.	1.9	12
41	Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia. <i>Brain Communications</i> , 2020, 2, .	3.3	20
42	Trajectory of apathy, cognition and neural correlates in the decades before symptoms in frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, e041821.	0.8	0
43	Neuropsychological Contribution to Predict Conversion to Dementia in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 785-796.	2.6	6
44	An exploration of prospective memory components and subtasks of the Memory for Intentions Test (MIST). <i>Journal of Clinical and Experimental Neuropsychology</i> , 2020, 42, 274-284.	1.3	5
45	Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 263-270.	1.9	106
46	Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 612-621.	1.9	55
47	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic <i>C9orf72</i> Repeat Expansion Adult Carriers. <i>Annals of Neurology</i> , 2020, 88, 113-122.	5.3	19
48	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. <i>Cortex</i> , 2020, 133, 384-398.	2.4	26
49	Can Subjective Memory Complaints Identify $A\beta$ Positive and $A\beta$ Negative Amnesic Mild Cognitive Impairment Patients?. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 1103-1111.	2.6	4
50	Mental time travel in mild cognitive impairment. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2019, 41, 845-855.	1.3	8
51	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. <i>Lancet Neurology</i> , The, 2019, 18, 1103-1111.	10.2	128
52	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. <i>Lancet Neurology</i> , The, 2019, 18, 1034-1044.	10.2	85
53	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. <i>NeuroImage</i> , 2019, 189, 645-654.	4.2	33
54	Online information and support for carers of people with young-onset dementia: A multi-site randomised controlled pilot study. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 1455-1464.	2.7	33

#	ARTICLE	IF	CITATIONS
55	Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 997-1004.	1.9	19
56	Education modulates brain maintenance in presymptomatic frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1124-1130.	1.9	23
57	Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC). <i>NeuroImage: Clinical</i> , 2019, 23, 101846.	2.7	18
58	Cerebral perfusion changes in presymptomatic genetic frontotemporal dementia: a GENFI study. <i>Brain</i> , 2019, 142, 1108-1120.	7.6	41
59	Ventricular volume expansion in presymptomatic genetic frontotemporal dementia. <i>Neurology</i> , 2019, 93, e1699-e1706.	1.1	19
60	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. <i>NeuroImage: Clinical</i> , 2019, 24, 102077.	2.7	27
61	Spatiotemporal analysis for detection of pre-symptomatic shape changes in neurodegenerative diseases: Initial application to the GENFI cohort. <i>NeuroImage</i> , 2019, 188, 282-290.	4.2	16
62	Neuropsychological Predictors of Long-Term (10 Years) Mild Cognitive Impairment Stability. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1703-1711.	2.6	14
63	Rare nonsynonymous variants in <i>SORT1</i> are associated with increased risk for frontotemporal dementia. <i>Neurobiology of Aging</i> , 2018, 66, 181.e3-181.e10.	3.1	19
64	Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study. <i>Neurobiology of Aging</i> , 2018, 62, 191-196.	3.1	151
65	Association of Cerebral Amyloid- $\beta$ Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	11.0	133
66	Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. <i>Neurobiology of Aging</i> , 2018, 62, 245.e9-245.e12.	3.1	40
67	Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort. <i>Neurobiology of Aging</i> , 2018, 62, 245.e1-245.e7.	3.1	16
68	Neuropsychological predictors of conversion from mild cognitive impairment to Alzheimer's disease: a feature selection ensemble combining stability and predictability. <i>BMC Medical Informatics and Decision Making</i> , 2018, 18, 137.	3.0	34
69	Can 11C-PiB-PET Relative Delivery R1 or 11C-PiB-PET Perfusion Replace 18F-FDG-PET in the Assessment of Brain Neurodegeneration?. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 89-97.	2.6	21
70	Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 639-652.	2.6	12
71	Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. <i>Nature Communications</i> , 2018, 9, 4273.	12.8	263
72	Memory complaints in amnesic Mild Cognitive Impairment: More prospective or retrospective?. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 1011-1018.	2.7	7

#	ARTICLE	IF	CITATIONS
73	Distinct patterns of brain atrophy in Genetic Frontotemporal Dementia Initiative (GENFI) cohort revealed by visual rating scales. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 46.	6.2	34
74	Presymptomatic white matter integrity loss in familial frontotemporal dementia in the <sc>GENFI</sc> cohort: A cross-sectional diffusion tensor imaging study. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1025-1036.	3.7	39
75	Distinct Neuroanatomical Correlates of Neuropsychiatric Symptoms in the Three Main Forms of Genetic Frontotemporal Dementia in the GENFI Cohort. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 1-16.	2.6	28
76	No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. <i>Neurobiology of Aging</i> , 2018, 69, 293.e9-293.e11.	3.1	15
77	Sustaining prospective memory functioning in amnesic mild cognitive impairment: A lifespan approach to the critical role of encoding.. <i>Neuropsychology</i> , 2018, 32, 634-644.	1.3	6
78	Cognitive reserve and TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a GENFI study. <i>Brain</i> , 2017, 140, 1784-1791.	7.6	55
79	Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease. <i>Acta Neuropathologica</i> , 2017, 134, 475-487.	7.7	53
80	White matter hyperintensities are seen only in GRN mutation carriers in the GENFI cohort. <i>NeuroImage: Clinical</i> , 2017, 15, 171-180.	2.7	63
81	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 111-126.	2.4	197
82	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 56, 33-40.	3.1	27
83	<i>TBK1</i> Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. <i>Human Mutation</i> , 2017, 38, 297-309.	2.5	87
84	[P4071]: EXOME SEQUENCING IN ATYPICAL FRONTOTEMPORAL DEMENTIA WITH PERIROLANDIC ATROPHY SUGGESTS A ROLE FOR MATRIX METALLOPROTEINASES IN FRONTOTEMPORAL DEMENTIA. <i>Alzheimer's and Dementia</i> , 2017, 13, P1285.	0.8	0
85	Personality of the caregiver influences the use of strategies to deal with the behavior of persons with dementia. <i>Geriatric Nursing</i> , 2017, 38, 63-69.	1.9	9
86	Enhanced LTP in aged rats: Detrimental or compensatory?. <i>Neuropharmacology</i> , 2017, 114, 12-19.	4.1	25
87	Delay discounting in mild cognitive impairment. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2017, 39, 336-346.	1.3	15
88	[IC0304]: WHITE MATTER HYPERINTENSITIES IN GENETIC FRONTOTEMPORAL DEMENTIA: A GENFI STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P9.	0.8	0
89	Adenosine Receptors and Memory Disorders. , 2017, , 175-186.		0
90	Predicting progression of mild cognitive impairment to dementia using neuropsychological data: a supervised learning approach using time windows. <i>BMC Medical Informatics and Decision Making</i> , 2017, 17, 110.	3.0	33

#	ARTICLE	IF	CITATIONS
91	Towards Trustworthy Predictions of Conversion from Mild Cognitive Impairment to Dementia: A Conformal Prediction Approach. <i>Advances in Intelligent Systems and Computing</i> , 2017, , 155-163.	0.6	2
92	Improving Prognostic Prediction from Mild Cognitive Impairment to Alzheimer's Disease Using Genetic Algorithms. <i>Advances in Intelligent Systems and Computing</i> , 2017, , 180-188.	0.6	6
93	Education modifies the type of subjective memory complaints in older people. <i>International Journal of Geriatric Psychiatry</i> , 2016, 31, 153-160.	2.7	21
94	Chocolate Consumption is Associated with a Lower Risk of Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 85-93.	2.6	57
95	RHAPSODY – Internet-based support for caregivers of people with young onset dementia: program design and methods of a pilot study. <i>International Psychogeriatrics</i> , 2016, 28, 2091-2099.	1.0	24
96	A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer's disease. <i>Acta Neuropathologica</i> , 2016, 132, 213-224.	7.7	83
97	Pittsburgh compound B imaging and cerebrospinal fluid amyloid- $\beta^2$ in a multicentre European memory clinic study. <i>Brain</i> , 2016, 139, 2540-2553.	7.6	107
98	Time Perception in Mild Cognitive Impairment: Interval Length and Subjective Passage of Time. <i>Journal of the International Neuropsychological Society</i> , 2016, 22, 755-764.	1.8	16
99	Depression with melancholic features is associated with higher long-term risk for dementia. <i>Journal of Affective Disorders</i> , 2016, 202, 220-229.	4.1	13
100	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. <i>Alzheimer's and Dementia</i> , 2016, 12, 154-163.	0.8	179
101	Rare Variants in <i>PLD3</i> Do Not Affect Risk for Early-Onset Alzheimer Disease in a European Consortium Cohort. <i>Human Mutation</i> , 2015, 36, 1226-1235.	2.5	23
102	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , 2015, 6, 216.	2.4	36
103	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. <i>Brain</i> , 2015, 138, 1327-1338.	7.6	284
104	Decrease in APP and CP mRNA expression supports impairment of iron export in Alzheimer's disease patients. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2015, 1852, 2116-2122.	3.8	33
105	Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. <i>Neurobiology of Aging</i> , 2015, 36, 2005.e15-2005.e22.	3.1	34
106	Classification of primary progressive aphasia: Do unsupervised data mining methods support a logopenic variant?. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2015, 16, 147-159.	1.7	13
107	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924.	7.4	1,166
108	Enhancing prospective memory in mild cognitive impairment: The role of enactment. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2015, 37, 863-877.	1.3	19

#	ARTICLE	IF	CITATIONS
109	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. <i>Alzheimer's and Dementia</i> , 2015, 11, 195.	0.8	56
110	Non-literal language deficits in mild cognitive impairment. <i>Psychogeriatrics</i> , 2014, 14, 222-228.	1.2	26
111	Significance of Subjective Memory Complaints in the Clinical Setting. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2014, 27, 259-265.	2.3	31
112	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2014, 128, 397-410.	7.7	93
113	Genetic and biochemical markers in patients with Alzheimer's disease support a concerted systemic iron homeostasis dysregulation. <i>Neurobiology of Aging</i> , 2014, 35, 777-785.	3.1	68
114	A Pan-European Study of the C9orf72 Repeat Associated with FTL: Geographic Prevalence, Genomic Instability, and Intermediate Repeats. <i>Human Mutation</i> , 2013, 34, 363-373.	2.5	247
115	Prediction of Long-Term (5 Years) Conversion to Dementia Using Neuropsychological Tests in a Memory Clinic Setting. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 681-689.	2.6	21
116	Rapidly progressive frontotemporal dementia and bulbar amyotrophic lateral sclerosis in Portuguese patients with C9orf72 mutation. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2013, 14, 70-72.	1.7	11
117	Class Imbalance in the Prediction of Dementia from Neuropsychological Data. <i>Lecture Notes in Computer Science</i> , 2013, , 138-151.	1.3	6
118	Quality of life in patients with mild cognitive impairment. <i>Aging and Mental Health</i> , 2013, 17, 287-292.	2.8	126
119	Quality of life in patients with cognitive impairment: validation of the Quality of Life "Alzheimer's Disease scale in Portugal. <i>International Psychogeriatrics</i> , 2013, 25, 1085-1096.	1.0	35
120	Phenotypic Variability of Familial and Sporadic Progranulin p.Gln257Profs*27 Mutation. <i>Journal of Alzheimer's Disease</i> , 2013, 37, 335-342.	2.6	9
121	Prediction of Dementia Patients: A Comparative Approach Using Parametric Versus Nonparametric Classifiers. <i>Studies in Theoretical and Applied Statistics, Selected Papers of the Statistical Societies</i> , 2013, , 269-280.	0.2	1
122	Rethinking Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2012, 3, 45.	2.4	8
123	Comparison of Four Verbal Memory Tests for the Diagnosis and Predictive Value of Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2012, 2, 120-131.	1.3	55
124	Epigenetic regulation of BACE1 in Alzheimer's disease patients and in transgenic mice. <i>Neuroscience</i> , 2012, 220, 256-266.	2.3	73
125	Serial position effects in Alzheimer's disease, mild cognitive impairment, and normal aging: Predictive value for conversion to dementia. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2012, 34, 841-852.	1.3	35
126	Speech Therapy in Primary Progressive Aphasia: A Pilot Study. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2012, 2, 321-331.	1.3	37



#	ARTICLE	IF	CITATIONS
127	Memory Complaints Associated with Seeking Clinical Care. <i>International Journal of Alzheimer's Disease</i> , 2012, 2012, 1-5.	2.0	25
128	Data mining methods in the prediction of Dementia: A real-data comparison of the accuracy, sensitivity and specificity of linear discriminant analysis, logistic regression, neural networks, support vector machines, classification trees and random forests. <i>BMC Research Notes</i> , 2011, 4, 299.	1.4	284
129	Assessment of dementia in ethnic minority patients in Europe: a European Alzheimer's Disease Consortium survey. <i>International Psychogeriatrics</i> , 2011, 23, 86-95.	1.0	104
130	Enhanced role of adenosine A2A receptors in the modulation of LTP in the rat hippocampus upon ageing. <i>European Journal of Neuroscience</i> , 2011, 34, 12-21.	2.6	149
131	The use of neuropsychological tests across Europe: the need for a consensus in the use of assessment tools for dementia. <i>European Journal of Neurology</i> , 2011, 18, 279-285.	3.3	42
132	Influence of personality on caregiver's burden, depression and distress related to the BPSD. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 1275-1282.	2.7	57
133	The Outcome of Elderly Patients with Cognitive Complaints but Normal Neuropsychological Tests. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 137-145.	2.6	35
134	Caffeine Intake is Associated with a Lower Risk of Cognitive Decline: A Cohort Study from Portugal. <i>Journal of Alzheimer's Disease</i> , 2010, 20, S175-S185.	2.6	83
135	Functional evaluation distinguishes MCI patients from healthy elderly people – The ADCS/MCI/ADL scale. <i>Journal of Nutrition, Health and Aging</i> , 2010, 14, 703-709.	3.3	83
136	Therapeutic Opportunities for Caffeine in Alzheimer's Disease and Other Neurodegenerative Disorders. <i>Journal of Alzheimer's Disease</i> , 2010, 20, S1-S2.	2.6	28
137	Memory Complaints Are Frequent but Qualitatively Different in Young and Elderly Healthy People. <i>Gerontology</i> , 2010, 56, 272-277.	2.8	77
138	Caffeine, Adenosine Receptors, and Synaptic Plasticity. <i>Journal of Alzheimer's Disease</i> , 2010, 20, S25-S34.	2.6	101
139	Electrophysiological Studies in Healthy Subjects Involving Caffeine. <i>Journal of Alzheimer's Disease</i> , 2010, 20, S63-S69.	2.6	17
140	Concluding Remarks. <i>Journal of Alzheimer's Disease</i> , 2010, 20, S249-S252.	2.6	7
141	Cognitive deficits in middle-aged and older adults with bipolar disorder and cognitive complaints: Comparison with mild cognitive impairment. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 624-631.	2.7	11
142	Memory complaints in healthy young and elderly adults: Reliability of memory reporting. <i>Aging and Mental Health</i> , 2008, 12, 177-182.	2.8	96
143	The neuroprotective effects of caffeine. <i>Neurology</i> , 2007, 69, 536-545.	1.1	320
144	Adenosine A2A receptors and brain injury: Broad spectrum of neuroprotection, multifaceted actions and caffeine tuning modulation. <i>Progress in Neurobiology</i> , 2007, 83, 310-331.	5.7	232

#	ARTICLE	IF	CITATIONS
145	Verbal learning and memory deficits in Mild Cognitive Impairment. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2007, 29, 187-197.	1.3	85
146	Aging and Cognitive Decline: Neuroprotective Strategies. , 2007, , 245-268.		0
147	Does caffeine modify corticomotor excitability?. <i>Neurophysiologie Clinique</i> , 2006, 36, 219-226.	2.2	48
148	Hypoxia-induced desensitization and internalization of adenosine A1 receptors in the rat hippocampus. <i>Neuroscience</i> , 2006, 138, 1195-1203.	2.3	65
149	Interaction Between P2X and Nicotinic Acetylcholine Receptors in Glutamate Nerve Terminals of the Rat Hippocampus. <i>Journal of Molecular Neuroscience</i> , 2006, 30, 173-176.	2.3	17
150	Mild Cognitive Impairment: Deficits in Cognitive Domains Other than Memory. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006, 21, 284-290.	1.5	74
151	Clinical significance of subcortical vascular disease in patients with mild cognitive impairment. <i>European Journal of Neurology</i> , 2005, 12, 125-130.	3.3	43
152	Long-term depression is not modulated by ATP receptors in the rat CA1 hippocampal region. <i>Neuroscience Letters</i> , 2005, 383, 345-349.	2.1	6
153	Mild Cognitive Impairment: Focus on Diagnosis. <i>Journal of Molecular Neuroscience</i> , 2004, 23, 143-148.	2.3	15
154	Decrease of adenosine A <sub>1</sub> receptor density and of adenosine neuromodulation in the hippocampus of kindled rats. <i>European Journal of Neuroscience</i> , 2003, 18, 820-828.	2.6	108
155	Adenosine promotes neuronal recovery from reactive oxygen species induced lesion in rat hippocampal slices. <i>Neuroscience Letters</i> , 2003, 339, 127-130.	2.1	43
156	Purinergic P2 receptors trigger adenosine release leading to adenosine A2A receptor activation and facilitation of long-term potentiation in rat hippocampal slices. <i>Neuroscience</i> , 2003, 122, 111-121.	2.3	53
157	Enhanced Adenosine A2A Receptor Facilitation of Synaptic Transmission in the Hippocampus of Aged Rats. <i>Journal of Neurophysiology</i> , 2003, 90, 1295-1303.	1.8	97
158	Participation of adenosine receptors in neuroprotection. <i>Drug News and Perspectives</i> , 2003, 16, 80.	1.5	77
159	Adenosine receptors in the nervous system: pathophysiological implications. <i>Progress in Neurobiology</i> , 2002, 68, 377-392.	5.7	452
160	Persistence of the neuromodulatory effects of adenosine on synaptic transmission after long-term potentiation and long-term depression. <i>Brain Research</i> , 2002, 932, 56-60.	2.2	18
161	Effects of Carbamazepine and Novel 10,11-Dihydro-5H -Dibenz [b,f ]Azepine-5-Carboxamide Derivatives on Synaptic Transmission in Rat Hippocampal Slices. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2002, 90, 208-213.	0.0	17
162	Does caffeine intake protect from Alzheimer's disease?. <i>European Journal of Neurology</i> , 2002, 9, 377-382.	3.3	317

#	ARTICLE	IF	CITATIONS
163	A functional role for adenosine A3 receptors: modulation of synaptic plasticity in the rat hippocampus. <i>Neuroscience Letters</i> , 2001, 302, 53-57.	2.1	46
164	Adenosine and synaptic plasticity. <i>Drug Development Research</i> , 2001, 52, 283-290.	2.9	41
165	Neuroprotection during hypoxic insults: Role of adenosine. <i>Drug Development Research</i> , 2001, 52, 291-295.	2.9	10
166	Adenosine receptor interactions in the hippocampus. <i>Drug Development Research</i> , 2001, 52, 337-345.	2.9	10
167	Presynaptic inhibitory receptors mediate the depression of synaptic transmission upon hypoxia in rat hippocampal slices. <i>Brain Research</i> , 2000, 869, 158-165.	2.2	48
168	Adenosine: does it have a neuroprotective role after all?. <i>Brain Research Reviews</i> , 2000, 33, 258-274.	9.0	224
169	Long-term potentiation observed upon blockade of adenosine A1 receptors in rat hippocampus is N-methyl-d-aspartate receptor-dependent. <i>Neuroscience Letters</i> , 2000, 291, 81-84.	2.1	38
170	Adenosine modulates synaptic plasticity in hippocampal slices from aged rats. <i>Brain Research</i> , 1999, 851, 228-234.	2.2	66
171	An Adenosine Analogue Inhibits NMDA Receptor-Mediated Responses in Bipolar Cells of the Rat Retina. <i>Experimental Eye Research</i> , 1999, 68, 367-370.	2.6	26
172	Endogenous Adenosine Attenuates Long-term Depression and Depotentiation in the CA1 Region of the Rat Hippocampus. <i>Neuropharmacology</i> , 1997, 36, 161-167.	4.1	73
173	Influence of metabotropic glutamate receptor agonists on the inhibitory effects of adenosine A1 receptor activation in the rat hippocampus. <i>British Journal of Pharmacology</i> , 1997, 121, 1541-1548.	5.4	29
174	Magnetic stimulation in Alzheimer's disease. <i>Journal of Neurology</i> , 1997, 244, 304-307.	3.6	60
175	Adenosine and neuronal plasticity. <i>Life Sciences</i> , 1996, 60, 245-251.	4.3	84
176	Adenosine by activating A1 receptors prevents GABAA-mediated actions during hypoxia in the rat hippocampus. <i>Brain Research</i> , 1996, 732, 261-266.	2.2	31
177	Control of NMDA receptors by adenosine: A new connection between coffee and excitation?. <i>NeuroReport</i> , 1995, 6, 1079.	1.2	0
178	Inhibition of NMDA receptor-mediated currents in isolated rat hippocampal neurones by adenosine A1 receptor activation. <i>NeuroReport</i> , 1995, 6, 1097-1100.	1.2	153
179	1,3-Dipropyl-8-cyclopentylxanthine attenuates the NMDA response to hypoxia in the rat hippocampus. <i>Brain Research</i> , 1994, 661, 265-273.	2.2	32
180	Endogenous adenosine modulates long-term potentiation in the hippocampus. <i>Neuroscience</i> , 1994, 62, 385-390.	2.3	121

#	ARTICLE	IF	CITATIONS
181	Adenosine inhibits the NMDA receptor-mediated excitatory postsynaptic potential in the hippocampus. Brain Research, 1993, 606, 351-356.	2.2	64
182	2-Chloroadenosine decreases long-term potentiation in the hippocampal CA1 area of the rat. Neuroscience Letters, 1990, 118, 107-111.	2.1	49